华东医药(000963.SZ)：罗氟司特乳膏收到药品注册受理通知书

Core Viewpoint - Huadong Medicine (000963.SZ) announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., received the Acceptance Notification from the National Medical Products Administration (NMPA) for the market approval application of Roflumilast Cream (ZORYVE) 0.3% [1] Group 1 - The active ingredient of ZORYVE is Roflumilast, which is a highly active and selective non-steroidal phosphodiesterase-4 (PDE4) inhibitor [1] - PDE4 is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases the production of anti-inflammatory mediators [1] - Inhibition of PDE4 can alleviate inflammatory responses [1]